Full Text View
Tabular View
No Study Results Posted
Related Studies
A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome
This study has been completed.
Study NCT00001123   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: January 17, 2000   Last Updated: November 11, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hantavirus Pulmonary Syndrome
Additional conditions recognized in this trial
Syndrome
More general conditions related to this trial
Bunyaviridae Infections
Disease
Hantavirus Infections
Pathologic Processes
Respiration Disorders
Respiratory Insufficiency
Respiratory Tract Diseases
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Ribavirin
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services